Related Experiment Video
Updated: Apr 18, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Role of E3 ubiquitin ligases in gastric cancer
1Ya-Chao Hou, Jing-Yu Deng, Department of Gastroenterology, Cancer Hospital of Tianjin Medical University, City Key Laboratory of Tianjin Cancer Center, and National Clinical Research Center of Cancer, Tianjin 300060, China.
Abstract:
E3 ubiquitin ligases have an important role in carcinogenesis and include a large family of proteins that catalyze the ubiquitination of many protein substrates for targeted degradation by the 26S proteasome. So far, E3 ubiquitin ligases have been reported to have a role in a variety of biological processes including cell cycle regulation, cell proliferation, and apoptosis. Recently, several kinds of E3 ubiquitin ligases were demonstrated to be generally highly expressed in gastric cancer (GC) tissues and to contribute to carcinogenesis. In this review, we summarize the current knowledge and information about the clinical significance of E3 ubiquitin ligases in GC. Bortezomib, a proteasome inhibitor, encouraged the evaluation of other components of the ubiquitin proteasome system for pharmaceutical intervention. The clinical value of novel treatment strategies targeting aberrant E3 ubiquitin ligases for GC are discussed in the review.
Insights
E3 ubiquitin ligases are highly expressed in gastric cancer, promoting its development. Targeting these ligases offers potential new treatments for gastric cancer patients.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- E3 ubiquitin ligases are crucial for protein degradation via the 26S proteasome.
- These ligases regulate vital cellular processes such as cell cycle, proliferation, and apoptosis.
- Aberrant E3 ubiquitin ligase expression is implicated in various cancers, including gastric cancer.
Purpose of the Study:
- To review the clinical significance of E3 ubiquitin ligases in gastric cancer (GC).
- To discuss the potential of targeting E3 ubiquitin ligases for novel GC therapies.
Main Methods:
- Literature review of current knowledge on E3 ubiquitin ligases in GC.
- Analysis of the role of E3 ubiquitin ligases in gastric carcinogenesis.
- Evaluation of pharmaceutical intervention strategies targeting the ubiquitin-proteasome system.
Main Results:
- E3 ubiquitin ligases are frequently overexpressed in GC tissues.
- These ligases contribute significantly to the development and progression of gastric cancer.
- The proteasome inhibitor Bortezomib highlights the therapeutic potential of targeting the ubiquitin-proteasome system.
Conclusions:
- E3 ubiquitin ligases represent important targets for gastric cancer treatment.
- Novel therapeutic strategies focusing on aberrant E3 ubiquitin ligases show promise for GC intervention.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Mitogens and the Cell Cycle
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Gastritis II: Pathophysiology
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

